# Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02093403** · PHASE1 · COMPLETED · sponsor: **Bhavana Bhatnagar** · enrollment: 25 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** decitabine
- **DRUG:** selinexor
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02093403
- **Lead sponsor:** Bhavana Bhatnagar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-11-26
- **Final completion:** 2016-11-26
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02093403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02093403, "Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02093403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*